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Abstract
Persistent infections of hepatitis C virus (HCV) are known to be a major risk factor for causing hepatocellular carcinomas.
Nonstructural protein 3 (NS3) of HCV has serine protease and RNA helicase domains, and is essential for the viral replication.
Further, NS3 is also considered to be involved in the development of HCV-induced hepatocellular carcinomas. In this report,
we focus on the function of NS3 protein, and propose a novel possible molecular mechanism which is thought to be related
to the tumorigenesis caused by the persistent infection of HCV. We identified SRCAP (Snf2-related CBP activator protein) as
a NS3 binding protein using yeast two-hybrid screening, and a co-immunoprecipitation assay demonstrated that NS3 can
bind to SRCAP in mammalian cells. The results of a reporter gene assay using Hes-1 promoter which is known to be a target
gene activated by Notch, indicate that NS3 and SRCAP cooperatively activate the Hes-1 promoter in Hep3B cells. In addition,
we show in this report that also p400, which is known as a protein closely resembling SRCAP, would be targeted by NS3.
NS3 exhibited binding activity also to the 1449–1808 region of p400 by a co-immunoprecipitation assay, and further the
activation of the Notch-mediated transcription of Hes-1 promoter by NS3 decreased significantly by the combined silencing
of SRCAP and p400 mRNA using short hairpin RNA. These results suggest that the HCV NS3 protein is involved in the
activation of the Notch-signaling pathway through the targeting to both SRCAP and p400.
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Introduction
The hepatitis C virus (HCV), a member of the Flaviviridae
family, is known as a major risk factor for hepatocellular car-
cinomas. Infection with HCV frequently becomes a persistent
infection and causes chronic hepatitis. During the course of long
term HCV infections, chronic hepatitis frequently develops hepatic
cancers through hepatic cirrhosis. The HCV has a single positive-
stranded RNA as the genome, and initially the viral proteins are
synthesized as a single polypeptide, and then the polypeptide is
cleaved by the viral and host cellular protease into the mature
components of the virus [1]. It has been reported that the viral
components, Core [2,3], NS3 (nonstructural protein 3) [4], NS4B
[5], and NS5A [6] independently indicate cell transforming acti-
vity, and these viral proteins are considered to be involved in the
tumorigenesis caused by HCV infection. One of these proteins,
NS3, has two enzymatic functions, serine protease [7–9] and RNA
helicase [10]. Like other viral proteins, NS3 is known as a
multifunctional protein which targets a variety of host factors and
modulates its function. For instance, it has been reported that the
HCV NS3 protein inhibits the protein kinase A (PKA) [11] and
PKC [12] functions, and like other HCV proteins, the Core [13]
and NS5A [14], p53 is also targeted by NS3 [4,15,16].
The Notch signaling pathway is evolutionarily conserved in
many species, and is responsible for cell differentiation and
proliferation [17,18]. Four Notch family genes have been iden-
tified in humans, and these genes encode transmembrane recep-
tors which recognize the membrane-associated ligands known as
Delta-1 like 1, 3, 4 and Jagged-1, 2. After the ligand binding to the
receptor form of Notch, the intracellular domain is released by
proteolytic cleavage, and the active form of Notch is translocated
into the nucleus where it activates target genes. Aberrant acti-
vation of the Notch-signaling pathway was observed in many
tumor cell lines, and is also found in cells derived from hepa-
tocellular carcinomas [19–22]. However it is known that the
Notch-signaling pathway indicates both a transform activity and
an anti-tumor activity depending on the status of the cell, in gen-
eral, it is considered that the Notch-signaling pathway represses
cell differentiation and promotes cell mitosis of stem cells [23,24].
Therefore the Notch-signaling pathway is important for the
maintainenance of homeostasis through the normal development
of cells, and dysfunction of the molecular mechanism to control
the Notch-signaling pathway is closely related to tumorigenesis.
Some reports have suggested that abnormality of the Notch-
signaling pathway contributes to tumorigenesis of hepatocellular
carcinomas [20–22], however, the effects of HCV viral infection
on the Notch-signaling pathway have not been clarified. In this
report, we focus on a NS3-binding molecule, and propose a novel
possible mechanism for tumorigenesis caused by the persistent
infection of HCV. We demonstrate that the HCV NS3 protein
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involved in the activation of the Notch-signaling pathway. The
SRCAP was found as a candidate molecule for an NS3 binding
protein by yeast two-hybrid screening which we have previously
performed using NS3 as a bait [25]. Originally, SRCAP was
identified as a binding partner of CBP (CREB binding protein)
belonging to the SNF2/SWI2 protein family, and acting as a
transcriptional activator [26]. Previously a report has indicated
that SRCAP is a mammalian homologue of the domino gene of
Drosophila melanogaster and is involved in the activation of Notch-
mediated transcription [27]. The amino acid sequence of SRCAP
has a significant similarity with p400 which is known to be targeted
by an adenovirus oncoprotein, E1A [28]. Also, p400 is known to
be a mammalian homologue of the domino gene, and is involved in
the tumorigenesis caused by adenovirus infection. From this, we
examined the p400 function in the Notch-signaling pathway, and
showed that also p400 is targeted by NS3 and involved in the
activation of the Notch-signaling pathway.
Results
HCV NS3 protein bind to SRCAP, the transcriptional co-
activator
To understand the molecular function of the HCV NS3 protein
in the tumorigenesis caused by HCV infection, we have previously
performed yeast two-hybrid screening against the HeLa cDNA
library to find NS3 binding proteins [25]. The screening yielded
several positive clones considered to be encoding NS3 binding
proteins, and one of the positive clones was identified as carrying
the SRCAP (Snf2-related CBP activator protein) mRNA. We
cloned SRCAP cDNA, and constructed mammalian expression
vectors for FLAG and HA-tagged SRCAP, and then the binding
activity of NS3 to the SRCAP in mammalian cells was in-
vestigated. The FLAG-tagged SRCAP and HA-tagged NS3 were
expressed in HEK293 cells and the whole cell extracts of the cells
were subjected to a co-immunoprecipitation assay using anti-
FLAG M2 agarose. The results indicated that HA-tagged NS3
were co-immunoprecipitated with FLAG-tagged SRCAP (Fig. 1A),
whereas no NS3 protein was detected in the immunoprecipitated
fraction of the control vector transfected cells. In addition, HA-
tagged SRCAP was co-immunoprecipitated with FLAG-tagged
NS3 when both proteins were expressed in HEK293 cells (Fig. 1B).
These data indicate that the NS3 protein exhibits binding activity
to SRCAP in mammalian cells. In addition, some low molecular
weight bands, considered to be degradation products of SRCAP,
were detected in the lanes of the whole extracts from SRCAP
transfected cells, however the patterns of these bands were not sig-
nificantly changed by expression of NS3. It has been reported that
NS4A is needed as a cofactor to fully activate NS3 protease fun-
ction. However, it is also known that NS3 expressed alone indi-
cates weak protease activity [29–31]. Therefore, the data suggest
that SRCAP is not a substrate of the proteolysis by NS3.
SRCAP is known to be a transcriptional factor, and is consi-
dered to be localized in nucleus [26]. On the other hand, previous
reports showed that subcellular localization of NS3 is mainly
observed in cytoplasm, and is especially accumulated to the endo-
plasmic reticulum (ER) [32. 33]. From these findings, we thought
the possibility that subcellular localization of NS3 is affected by the
expression of SRCAP. To examine this possibility, we separated the
HEK293cells whichwere transfected with the expression vectors for
FLAG-tagged NS3 and SRCAP proteins into nuclear and post-
nuclear fractions, and analyzed these fractions by Western blotting.
As shown in Fig. 1C, the results show that nuclear-localized NS3
protein was significantly increased by the co-expression of SRCAP.
These observations suggested the possibility that a function of
SRCAP is modulated by the NS3 in nucleus.
HCV NS3 protein enhances both Notch1- and Notch3-
induced Hes-1 promoter activation cooperatively with
SRCAP
The SRCAP protein has been found to be a transcription factor
belonging to the SNF/SWI family [26]. It has been reported that
SACAP is a mammalian homologue of the domino gene product of
Drosophila melanogaster, and that it is responsible for activating the
Notch-signaling pathway [27]. From these findings, we thought
that NS3 might affect the Notch-signaling pathway through
binding to SRCAP. To investigate the effects of the NS3 protein
against SRCAP mediated Notch-signaling activation, we per-
formed a reporter gene assay.
It has been reported that aberrant expression of Notch3 is found
in many hepatocellular carcinoma cells, as frequently as that of
Notch1 [19–22]. Thus, we initially constructed expression vectors
for the intracellular region of human Notch1 (Notch1 IC) and
Notch3 (Notch3 IC). Although the functional differences between
Notch1 and Notch3 were not established, as shown in Fig. 2A, in
the structural features, Notch3 has a shorter extracellular EGF-like
domain and transactivation domain than Notch1 [17,18]. Both
Notch1 and Notch3 have an extracellular domain for recognition
of the stimulation by the ligands, and the intracellular region
contains nuclear localization signals and a transactivation domain.
By stimulation of the ligand, the intracellular region is cleaved and
translocated to the nucleus, and then activates the target genes.
Therefore, the intracellular region of Notch is known to act as the
active form of Notch. Western blotting analysis of the expression of
Notch1 IC and Notch3 IC in HEK293 cells indicated that both of
these proteins were well expressed and exhibited similar expression
efficiencies (Fig. 2B).
Next, we investigated the effects of the NS3 expression on the
Notch-signaling pathway using reporter gene assay using a reporter
plasmid containing the firefly luciferase gene under the control of
Hes-1 (hairy and enhancer of split 1) promoter; Hes-1 is known as a
target gene activated by Notch, and a reporter construct using Hes-1
gene promoter is widely used for monitoring activation of the Notch-
signaling pathway [34]. The reporter plasmids, NS3 and SRCAP
expression vectors were transfected into Hep3B cells together with
the plasmid expressing Notch1 IC or Notch3 IC. After 48 hrs, the
activation of the Hes-1 promoter was monitored by the luciferase
activityusing a luminometer. The results show that activation ofHes-
1 promoter by Notch1 IC was significantly enhanced by over-
expression of SRCAP and NS3 (Fig. 2C). Comparable results were
obtained by the Notch3 IC mediated activation of Hes-1 promoter.
As shown in Fig. 2D, activation of Hes-1 promoter mediated by the
expression of Notch3 ICwas significantly increased bythe combined
expression of NS3 and SRCAP. These results indicate that NS3 and
SRCAP proteins cooperatively activate Notch-signaling pathway in
a transcription level.
Protease activity of NS3 is not required for the activation
of Notch signaling pathway by NS3
As shown in Fig. 3A, NS3 has two catalytic domains, one is a
serine protease domain which is located at the N-terminus one
third of NS3, and other is an RNA helicase domain at the C-
terminus. A previous report indicates that the transforming activity
of NS3 can be assigned to the N-terminus protease region [4], and
this region was also used as the bait for our previously performed
yeast two-hybrid screening [25]. To verify this, we investigated
whether the N-terminal portion of NS3 (the 1011 to 1295 amino
HCV NS3 Can Activate Notch-Signaling Pathway
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a co-immunoprecipitation assay. The results showed that the N-
terminal portion of the NS3 protein also exhibits binding activity
to SRCAP (Fig. 3B), in agreement with the result of the yeast two-
hybrid screening.
Next, we investigated function of the N-terminal portion of NS3
for the Notch-mediated transcription of the Hes-1 promoter. The
results show that although the activity of the N-terminal portion of
NS3 was weaker than the full-length NS3, the N-terminal portion
of NS3 also activated the Notch1 IC-mediated transcription of
Hes-1 promoter (Fig. 3C). The result suggests that function of NS3
for activation of Notch-signaling is assigned in N-terminal protease
region of NS3. Thus, we investigated whether the protease activity
of NS3 is involved in the activation of the Notch-mediated
transcription. The N-terminal portion of NS3 or of the protease-
dead mutant NS3 (Fig. 3A) [7] fused with EGFP (enhanced green
fluorescent protein) was transfected into Hep3B cells, and the
reporter gene activities under the control of Hes-1 promoter were
monitored. The results show that both the N-terminal portion of
NS3 and its protease-dead mutant activated the Notch1 IC
induced transcription of the Hes-1 promoter (Fig. 3D). These data
suggest that the protease activity of NS3 is not required for the
activation of Notch-mediated transcription.
Finally, to investigate whether the NS3 function for activation of
Notch-signaling pathway is also functional under the condition of
which the other HCV proteins exist, we performed the reporter
gene assay using expression vector for full-length HCV poly-
protein. The results show that Notch1 IC-mediated activation of
Figure 1. Identification of SRCAP as a host factor which is targeted by HCV NS3. (A, B) HEK293 cells were transfected with the expression
vectors for HA-tagged NS3 and FLAG-tagged SRCAP (A), or the expression vectors for HA-tagged SRCAP and FLAG-tagged NS3 (B). After 48 hrs, the cells
were harvested and the whole cell lysates were subjected to the immunoprecipitation assay using anti-FLAG M2 agarose (Sigma) as described in the
Materials and Methods.The asterisk (*) indicatesthebandswhichare consideredtobedegradation products ofexogenouslyexpressedSRCAP.(C) HEK293
cells were transfected with expression vectors for FLAG-tagged NS3 and SRCAP proteins. After 24 hrs, the cells were harvested, and were fractionated into
nuclear and post-nuclear fractions. Anti-histon H1 and anti-actin antibodies were used as a nuclear control and a loading control, respectively.
doi:10.1371/journal.pone.0020718.g001
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HCV polyprotein (Fig 3E).
NS3 also binds to the fragment of p400 which is
homologous to the NS3-binding region of SRCAP
Sequence analysis showed that the positive clone obtained by
the yeast two-hybrid screening encodes the 1639–1990 amino-acid
region of SRCAP (Fig. 4A). To investigate whether this region of
SRCAP is responsible for the binding to NS3, we constructed a
plasmid to express this region of SRCAP and performed a
co-immunoprecipitation assay. The results show that HA-tagged
SRCAP 1639–1990 was co-immunoprecipitated with FLAG-
tagged-NS3 (Fig. 4C), suggesting that this region which almost
fully overlaps the previously reported CBP binding site of SRCAP
(amino acid position 1649–1988; note that the position of the
amino acid has been changed from the previously reported
numbers, because the sequence of SRCAP in the database has
been updated.) [26] is responsible for binding to NS3.
There is a significant sequence similarity of SRCAP with p400,
which is known as a transcriptional factor binding to the
Figure 2. NS3 and SRCAP cooperatively activate Notch-mediated transcription of Hes-1 promoter. (A) Schematic illustration of domain
structure of human Notch1 and Notch3. The amino acid positions of the intracellular domains of Nocth1 and Notch3 are indicated in the figure. EGF-
like, EGF-like domain; LNR, LIN12/Notch repeats; TM, transmembrane region; RAM, RAM (RBP-jk-associated molecule) domain; NLS, nuclear
localization signal; ANK, ankyrin repeat; TAD, transactivation domain; PEST, PEST (proline (P)-, glutamic acid (E)-, serine (S)- and threonine (T)-rich)
sequence. (B) Protein expression analysis of FLAG-tagged intracellular (IC) domain of Notch1 and Notch3. The expression vector for FLAG-tagged
Notch1 IC or Notch3 IC was transfected into HEK293 cells. After 24 hrs, the whole cell extracts were subjected to the immuno-blotting analysis using
anti-FLAG antibody. (C, D) The expression vectors for FLAG-tagged Notch1 IC (C), or Notch3 IC (D) and the expression plasmids for FLAG-tagged NS3
and SRCAP were transfected into Hep3B cells together with reporter constructs, pGL4.20 Hes-1 pro and pcDNA3.1 (+) Rluc. After 48 hr, the luciferase
activities were quantified by luminometer. The relative Hes-1 promoter activities are expressed in relative luminescence units (RLU) normalized by
Renilla luciferase activities. Error bars indicating the standard deviations were calculated from at least three independent experiments.
doi:10.1371/journal.pone.0020718.g002
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showed that the region homologous to the p400 for the NS3
binding region of SRCAP can be assigned to amino acid position
1450–1808 (Fig. 4A and 4B). We constructed a HA-tagged
expression vector for this region by cloning, and performed a co-
immunoprecipitation assay to investigate the binding activity of
NS3 to this region. The results showed that NS3 is also able to
bind to this region of p400 (Fig. 4D). The data suggest that p400
must be considered a candidate for host-cellular molecules
targeted by NS3 as well as by SRCAP.
Gene specific silencing of SRCAP and p400 mRNAs by
short hairpin RNAs inhibits the NS3-mediated activation
of Hes-1 promoter
To investigate the effect of SRCAP knockdown in relation to the
enhancement of Notch-mediated activation of Hes-1 promoter by
Figure 3. Protease activity of NS3 is not required for activation of Notch-signaling pathway. (A) Schematic diagram of the NS3 deletion
mutant and its protease deficient mutant used in this study. The amino acid residues of the serine protease catalytic triad and the conserved motifs of
helicases are indicated in the figure. (B) The expression vector for the HA-tagged N-terminal protease region of NS3 and FLAG-tagged SRCAP were
transfected into HEK293 cells. After 48 hrs, the whole extracts from the cells were immunoprecipitated with anti-FLAG agarose (Sigma), and the
immunoprecipitated fractions were analyzed by immunoblotting. (C) The expression vector for FLAG-tagged NS3 or the N-terminal portion of NS3 and
the expression plasmid for Notch1 IC were transfected into Hep3B cells together with pGL4.20 Hes-1 pro and pcDNA3.1 (+) Rluc. After 48 hrs, the
luciferase activities were quantified by luminometer. (D) The EGFP-fused N-terminal protease region of NS3 or its protease deficient mutant was
transfected into Hep3B cells together with the Notch1 IC expression vector, pGL4.20 Hes-1 pro and pcDNA3.1 (+) Rluc. After 48 hrs, luciferase activities
were measured by luminometer. (E) Theexpression vectors for full-length HCV polyprotein andfor Notch1IC were transfected into Hep3B cellstogether
with the reporter gene constructs. After 48 hrs, luciferase activities were quantified. The relative Hes-1 promoter activities are expressed in RLU
normalized by Renilla luciferase activities. Error bars indicating the standard deviations were calculated from at least three independent experiments.
doi:10.1371/journal.pone.0020718.g003
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PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e20718Figure 4. NS3 binds to the amino acid region 1449–1808 of the p400 protein. (A) Schematic illustration of domain structure of human
SRCAP and p400. The domain structures predicted by using conserved domain database (CDD) are indicated in the figure. HAS, helicase-SANT-
associated (HSA) domain; SNF2N, SNF2 family N-terminal domain; DEXDc, DEAD-like helicases superfamily domain; CBPid, CBP interaction domain;
NS3 bd, HCV NS3 protein binding domain; HELICc, Helicase superfamily c-terminal domain. (B) Amino acid sequence alignment of the NS3-binding
region of SRCAP and its equivalent region in p400. The NS3 binding region of SRCAP (amino acid position: 1639–1990) was aligned with the p400
sequence using CLUSTAL W [62]. Identical amino acids are shown in gray. (C, D) The expression vector for HA-tagged SRCAP (1639–1990) (C) or p400
(1449–1808) (D) was transfected into HEK293 cells together with the expression plasmid for FLAG-tagged NS3. After 24 hrs, the cells were harvested,
lysed, and then subjected to the co-immunoprecipitation analysis using anti-FLAG M2 agarose (Sigma).
doi:10.1371/journal.pone.0020718.g004
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hairpin RNA (shRNA) to specifically silence the SRCAP mRNA
expression via RNA interference. However, the knockdown of
SRCAP mRNA did not significantly affect the activation of the Hes-1
promoter (data not shown). As shown in Fig. 4D, the results of the
co-immunoprecipitation assay showed that NS3 also exhibits
binding activity to a partial coding region of p400 which is a
protein closely related to SRCAP. This finding suggested the
possibility that both SRCAP and p400 are involved in the
enhancement of Notch-mediated Hes-1 promoter activation by
NS3. To evaluate this, we constructed a plasmid vector to express
shRNA which specifically silences the gene expression of p400 in
addition to the shRNA expression vector for SRCAP. These shRNA
expression vectors were transfected into HEK293 cells and the
expression levels of SRCAP and p400 mRNAs were quantified by
real-time RT-PCR to confirm the gene silencing efficiency of these
shRNAs expression vectors against endogenously expressed SRCAP
and p400 mRNA. The results show that endogenously expressed
SRCAP and p400 mRNAs were efficiently repressed by the
transfection of the expression vector for SRCAP and p400 specific
shRNA (Fig. 5A and 5B). Comparable results were obtained by
Western blotting analysis. As shown in Fig. 5C and 5D, the
expression of SRCAP and p400 proteins was significantly repressed
by the expression of these gene specific shRNAs.
Next, to investigate the effects of gene silencing of SRCAP and
p400 on the Notch-signaling pathway, we performed a reporter
gene assay. The HEK293 cells were transfected with the shRNA
expression vectors. After 48 hrs, the cells were transfected with the
reporter gene construct together with Notch1 IC and NS3
expression vectors. After an additional 48 hr of incubation of the
post-transfection, the luciferase activities were measured by a
luminometer. Unexpectedly, the results show that NS3-mediated
activation of Hes-1 promoter induced by Notch1 IC is enhanced
by the knockdown of SRCAP mRNA, suggesting that SRCAP
negatively regulates Notch1 IC-mediated Hes-1 promoter activa-
tion in HEK293 cells (Fig. 5E). These results were contradictory to
the results of the reporter gene assay indicating the effect of the
SRCAP overexpression in Hep3B cells (Fig. 2C). In addition, the
Notch1 IC-induced Hes-1 promoter activations were strongly
repressed by the knockdown of p400 mRNA, suggesting that p400
is predominantly responsible for activation of the Notch-signaling
pathway in HEK293 cells. The mammalian cell line, HEK293 has
been established from a transformed cell by the integration of
adenovirus type 5 DNA into the genome of human embryonic
kidney cells [35], and is constitutively expressing adenovirus E1A
protein. Since it is known that SRCAP and p400-mediated
transcriptions are modulated by E1A [26,28], it is likely that the
adenovirus E1A protein expressed in HEK293 cells would affect
the results. Based on this hypothesis, Hep3B cells were used to re-
examine the effects of the gene silencing of SRCAP and p400
mRNA on the Notch-signaling pathway. The results indicate a
slight (but not statistically significant) inhibition of the NS3
function to the Hes-1 promoter activation by the independent
knockdown of SRCAP or p400 mRNA (Fig. 5F). In addition, the
combined knockdown of SRCAP and p400 mRNAs statistically
significantly (P,0.01) inhibited the NS3-mediated Hes-1 promoter
activation. These results indicate that both SRCAP and p400 are
involved in the NS3-mediated activation of Hes-1 promoter.
Discussion
In this report, we demonstrated that HCV NS3 protein can
bind to a host-cellular transcriptional factor, SRCAP, and enhance
the Notch-mediated transcriptional activation of Hes-1 promoter
cooperatively with SRCAP by the overexpression. However it is
not clarified whether the NS3-mediated activation of Notch-
signaling is also functional in HCV-infected cells, and further
investigations under more physiological conditions are required to
confirm the significance of of our findings on the life cycles of
HCV. Nevertheless, as discussed below, at least the Notch-
signaling seems to be activated in the HCV patient’s liver, and is
thought to be involved in the tumorigenesis caused by the per-
sistent infection of HCV.
A previous report has demonstrated that the expressions of
Notch1 and its ligand Jagged-1 were increased in hepatocytes after
partial hepatectomy [36]. The study here indicates the importance
of Notch-signaling in liver regeneration, and suggests the
possibility that tissue damage to the liver caused by the infection
of HCV activates Notch-signaling. It has been reported that the
Notch-signaling pathway exhibits both pro-tumor and anti-tumor
activity [23,24]. Although increments in Notch expression is
frequently observed in hepatocellular carcinoma cells [19–22],
Notch also exhibits inhibitory activity to cell proliferation of
hepatocellular carcinomas [37]. In addition, Notch exhibits both
pro-apoptotic and anti-apoptotic functions towards hepatocellular
carcinoma cells [38,39]. Generally, the Notch-signaling pathway is
responsible for maintaining cells at the proliferative and undif-
ferentiated states. Therefore, whether Notch promotes or sup-
presses tumorigenesis is thought to be mostly dependent on the
status of the cells. Like Notch-signaling indicates invertible fun-
ctions dependent on the status of the cells, NS3 exhibits not only
the function to promote cell proliferation [40] and to inhibit
induction of apoptosis [16], but also activity for induction of apo-
ptosis [41]. The NS3 function for activation of the Notch-signaling
pathway may provide a part of the reason for these countervailing
functions of NS3.
Constitutive activation of Notch-signaling is frequently observed
in human hepatocellular carcinoma and is also found in the
carcinomas caused by HCV infection [20,21]. The activation of
Notch-signaling induces expression of its membrane-bound
ligands known as Delta-1 like 1, 3, 4 and Jagged-1, 2, and then,
these expressed ligands stimulate Notch receptor expressed on the
surface of other cells by cell-to-cell contact [17,18].This activation
loop of Notch-signaling may have some advantages for the effec-
tive replication of HCV through the activation of cell proliferation
of HCV-infected cells, and lead to constitutive activation of Notch
during the course of tumor development.
The co-immunoprecipitation assay using partial coding regions
of SRCAP showed that the binding region of NS3 on SRCAP is
assigned to a region almost overlapping with the CBP-binding
region of SRCAP (Fig. 4A and 4C). Since interaction with CBP is
crucial for the transcriptional activation function of SRCAP [26
42], NS3 may be involved in recruitment of CBP/p300 to
SRCAP, or stabilization of CBP/p300 and SRCAP complexes. In
addition, the study here demonstrates that NS3 also binds to the
partial coding region of p400 which is homologous with the NS3
binding region of SRCAP (Fig. 4D). Although whether NS3 is
actually binding to p400 is not clarified, the gene silencing experi-
ment data here using SRCAP and p400 specific shRNAs demon-
strates that both SRCAP as well as p400 are involved in NS3-
mediated activation of the Notch-signaling pathway (Fig. 5). Both
SRCAP and p400 are known to be p300/CBP binding proteins
[26,28] and previous reports have demonstrated that p300/CBP is
important for activation of the Notch signaling pathway [43,44].
Therefore it would be quite possible that both SRCAP and p400
are involved in the activation of the Notch-mediated transcription.
Originally, p400 has been identified as an adenovirus E1A-
binding molecule and is considered to be involved in the
HCV NS3 Can Activate Notch-Signaling Pathway
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also binds to p300 and other host-cellular transcriptional factors,
and is thought to be involved in transcriptional regulation by
formation of the complex with these factors [45,46]. At the same
time, the previous reports have demonstrated that SRCAP-
mediated transcriptional activation is inhibited by E1A through
the prevention of the interaction of SRCAP and CBP [26,47].
Taken together, these findings suggest the possibility that E1A
plays a role different from NS3 in the activation of Notch-
mediated transcription through the modulation of the transcrip-
tional function of SRCAP and p400. The results of the reporter
gene assay using HEK293 cells suggest a distinct function of E1A
on SRCAP and p400-mediated activation of Notch-signaling
(Fig. 5E). The observations indicate that the Notch1 IC-mediated
activation of Hes-1 promoter was strongly suppressed by the
knockdown of p400, while the knockdown of SRCAP resulted in no
such effect. Here, the enhancement of activation of Hes-1 pro-
moter by NS3 is increased by the knockdown of SRCAP mRNA. A
mechanism to explain these phenomena is indicated in Fig. 6. The
HCV NS3 protein activates the transcriptional activator function
of both SRCAP and p400, whereas the adenoviral E1A protein
activates only the function of p400, but inhibits the SRCAP-
mediated transcriptional activation as previously reported [26,47].
The functions of NS3 and E1A in the modulation of a transcrip-
tional activator function of SRCAP appear to act in a competitive
manner, while at the same time NS3 and E1A are thought to be
regulating the p400 function in a coordinative manner. Therefore,
the SRCAP dependent activation of Notch1 IC-mediated tran-
scription of Hes-1 promoter is repressed by the competition of the
NS3 and E1A functions in the p400 knockdown HEK293 cells,
while a p400 dependent activation of Notch1 IC is coordinately
increased by NS3 and E1A proteins in the SRCAP knockdown cells
(Fig. 5E). In addition, the effects of the knockdown of p400 were
partially restored by the additional knockdown of SRCAP mRNA.
These results would indicate that the molecular ratio of SRCAP
and p400 is important for the activation of Notch-mediated tran-
scription by E1A.
It has been reported that knockdown of SRCAP mRNA re-
presses replication of HCV [48]. This systematic RNAi screening
study indicated that about 4.9 fold decrement of the HCV
replication and about 1.4 fold decrement of the RNA replication
of HCV replicon were observed by the knockdown of SRCAP.
Although the dependence on Notch-signaling pathway in this
phenomenon is not clarified, the report demonstrated the sig-
nificance of SRCAP on the effective replication of HCV. On the
other hand, a previous report has demonstrated that SRCAP is
also targeted by the NS5A protein of HCV [49]. That report
indicated that NS5A exhibits binding activity to SRCAP and
cooperatively inhibits transcriptional activation of p21 promoter
which is a well known target gene regulated by p53. Although the
NS5A function for modulating Notch-signaling through the
binding to SRCAP has not been clarified, the results of reporter
gene assay using expression vector for full length HCV polyprotein
indicate that at least NS3-mediated activation of Notch-signaling
seems to be not inhibited by the expression of NS5A (Fig, 3E).
Thus far, the focus here has been on the SRCAP function for
activation of Notch-mediated transcription, and it has been pos-
sible to show the potential of NS3 for the enhancement of SRCAP-
mediated activation of the Notch-signaling pathway. However,
SRCAP is also known to be responsible for the regulation of other
Figure 5. Combinational knockdown of SRCAP and p400 inhibits the NS3 function for the Notch-signaling pathway. (A, B) Analysis of
the gene silencing efficiency of the shRNA expression vectors used in this study. The SRCAP or p400 targeted shRNA expression vector was
transfected into HEK293 cells. The total amount of the expression vectors for shRNA in each transfections were equalized using the control shRNA
expression vector. After 48 hrs, the cells were harvested, and the expression levels of SRCAP (A) and p400 (B) mRNAs were quantified by real-time RT-
PCR. Data represent relative expression amount compared with that of non-specific shRNA-transfected cells. Error bars indicate standard deviations
calculated by at least three independent experiments. (C, D) The protein expression levels of SRCAP and p400 in shRNA-transfected HEK293 cells were
analyzed by Western blotting using specific antibodies against SRCAP and p400. Actin was used for loading control. (E, F) The HEK293 (E) or the
Hep3B (F) cells were transfected with expression vectors for SRCAP and p400 specific shRNAs. After 48 hrs, the cells were transfected with reporter
gene constructs together with FLAG-tagged Notch1 IC and NS3 expression vectors. After an additional 48 hr incubation period of post-transfection,
the luciferase activities were measured using a Dual-Glo luciferase assay kit by luminometer. The relative Hes-1 promoter activities are expressed in
RLU normalized by Renilla luciferase activities. Error bars indicate standard deviations calculated by at least three independent experiments.
doi:10.1371/journal.pone.0020718.g005
Figure 6. Proposed mechanism of HCV NS3 and adenovirus E1A in the Notch-mediated transcription. The HCV NS3 protein activates
both the SRCAP and p400 functions for the Notch-mediated transcription, whereas adenovirus E1A protein activates only the p400 function. Since
E1A disrupts the interaction of p300 and p400, enhancement of SRCAP-mediated transcriptional activation of Notch target genes by NS3 is inhibited
by the competition with the E1A function. The NS3 function for p400-mediated transcriptional activation is not competitive with the E1A function.
Thus an additional expression of NS3 enhances the E1A function for increments in the p400-mediated transcriptional activation.
doi:10.1371/journal.pone.0020718.g006
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analyze the function of SRCAP in the regulation of p53 for a
further understanding of the tumorigenesis caused by HCV
infections. Transcription of p53 target genes is modulated by
SRCAP [50] and p400 [51], and also by p300/CBP which is a
binding partner of SRCAP, and p400 is important for regulation
of the functions of p53 [52–54]. Moreover, p53 is known to be a
host-cellular molecule targeted by HCV Core protein [13].
Therefore the function of NS3 in the modulation of SRCAP-
mediated transcriptional activation is thought to be affected by the
function of Core protein in addition to that of NS5A. Further
investigation to analyze the functional relationship of NS3 and the
other HCV molecules in the modulation of SRCAP and SRCAP-
related molecules will be necessary for a fuller understanding of the
detailed molecular mechanism of tumorigenesis caused by HCV
infections.
Materials and Methods
Cell culture and transfection
The human embryonic kidney cell line HEK293 [35] and the
human hepatocellular carcinoma cell line Hep3B [55] were
maintained in DMEM (Sigma, St. Louis, MO) and RPMI 1640
(Sigma) respectively. Each medium supplemented with 10% FCS,
100 units/ml penicillin and 100 mg/ml streptomycin, and the cells
were grown at 37uC with 5% CO2.
Transfections were performed using FuGENE HD (Roche,
Mannheim, Germany), X-tremeGENE HP (Roche) or Lipofecta-
mine 2000 (Invitrogen, Carlsbad, CA) according to the manufac-
turer’s protocols.
Vector Construction
The expression vector for full-length HCV polyprotein,
pCAG394, was kindly provided by Dr. Hideaki Aizaki (National
Institute of Infectious Diseases, Tokyo, Japan) [56,57].
To construct epitope tagged SRCAP expression vectors, almost
the entire SRCAP cording region (accession number: NM_00
6662; amino-acid position: 198–3230) was amplified by PCR from
the HeLa cDNA library using specific sense primer (59- GA-
TCGGATCCATGGCCAAGGATGTCAGGCA -39) and anti-
sense primer (59- GATCGAATTCTCACGTCTTGGCCTTGC-
GGC -39). The amplified cDNA was digested with BamHI and
EcoRI sites integrated in the primers, and inserted into the same
site of pcDNA3 FLAG and pcDNA3.1 (+) HA (N). The partial
coding region of SRCAP (amino-acid position: 1639–1990) was
expressed as a dual epitope-tagged protein carrying the myc and
HA tags at the N- and C-terminus, respectively. The 1639–1990
amino-acid region of SRCAP was amplified by PCR using sense
primer (59- CTGGATCCGGAACCTCTTTAGCCTCAGCTT -
39) and antisense primer (59- CAGAATTCCAGGGAAGGGG-
GAGGTGCCTCC -39) from the SRCAP cDNA, and inserted at
the BamHI-EcoRI site of pcDNA3.1 (+) MYC-HA. The part of the
human p400 coding sequence which is homologous to the SRCAP
NS3 binding region (accession number: NM_015409; amino-acid
position: 1449–1808) was amplified by RT-PCR using sense
primer (59- CTGGATCCCCCCGGACGGCAGCCCCCACCA
-39) and antisense primer (59- GGCTCGAGTAGGGACGG-
GGGTGCTGCCACC -39) from HEK293 cells, and inserted into
the BamHI-XhoI site of pcDNA 3.1(+) HA (N).
To construct expression plasmids for FLAG- and HA-tagged
NS3, the cDNA fragment which encodes NS3 protein (amino-acid
position: 1011–1608) derived from the HCV subtype 1 b was
amplified by PCR using sense primmer (59- CGCCGGATCCC-
CACTTCTAGGACCGGCCGA -39) and antisense primer
(59- AGGAATTCCTACCACATTTGATCCCACGAT -39) from
the cloned cDNA [58], and inserted into the BamHI-EcoRI site of
pcDNA3 FLAG and pcDNA3.1 (+) HA (N), respectively. The
plasmid expressing FLAG-tagged N-terminal portion of NS3
(amino-acid position: 1011–1295) is described in elsewhere, and
the coding region of the N-terminal portion of NS3 was inserted
into pcDNA3.1 (+) HA (N) for construction of a HA-tagged
plasmid. To construct expression plasmids for an EGFP (enhanced
green fluorescent protein) fused N-terminal portion of NS3, the
EcoRI-BamHI fragments carrying the NS3 cording region from
pGBT/NS3N or pGBT/NS3N/S1165A [25] were inserted into
the same site of pEGFP-c2 (Clontech, Mountain View, CA).
The reporter plasmid carrying the promoter region of the
murine Hes-1 gene was constructed as previously described [34],
except pGL4.20 (Promega, San Luis Obispo, CA) was used instead
of pGL2 Basic. For construction of the vector expressing the
constitutive active form of Notch1 and Notch3, the cDNA en-
coding intracellular domain of human Notch1 (accession number:
NM_017617; amino-acid position: 1759–2556) was amplified by
RT-PCR using sense primer (59- CCGGATCCCGCCGGCGG-
CAGCATGGCCAGC-39) and antisense primer (59- CGCTCGA-
GTTACTTGAAGGCCTCCGGAATG -39) from K562 cells
[59], and the intracellular domain of human Notch3 (accession
number: NM_000435; amino-acid position: 1663–2321) was
obtained by RT-PCR using sense primer (59- TGGGATC-
CATGGTGGCCCGGCGCAAGCGCGA -39) and antisense
primer (59- CGCTCGAGTCAGGCCAACACTTGCCTCTTG
-39) from HEK293 cells. Each amplified fragment was inserted
into the BamHI-XhoI site of pcDNA3 FLAG.
To construct shRNA expressing vectors silencing the SRCAP
and p400 genes, we used previously reported target sequences
which are specifically repressed gene expressions of SRCAP [60]
and p400 [61]. Double stranded synthetic oligonucleotide were
ligated into pSilencer 5.1-U6 Retro (Applied biosystems, Foster
City, CA) according to the manufacturer’s protocol, and pSilencer
5.1-U6 Retro Scrambled (Applied biosystems) was used for the
control vector which is expressing nonspecific shRNA.
Immunoprecipitation
Expression vectors for epitope-tagged NS3 (1.0 mg) and SRCAP
(3.0 mg) or derivatives of these plasmids were transfected into HEK
293 cells. After 24 hrs, cells were harvested and lysed by RIPA
buffer (25 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1% NP-40,
1% sodium deoxycholate, 0.1% SDS) supplemented with a
protease inhibitor cocktail (Complete Mini; Roche). After the cell
debris was removed by centrifugation, the lysates were subjected to
immunoprecipitation using anti-FLAG M2 agarose (Sigma). The
resins were washed five times with RIPA buffer and eluted binding
proteins by boiling for 5 min with 2 x SDS-PAGE gel-loading
buffer (125 mM Tris-HCl [pH 6.8], 5% b-mercaptoethanol, 4%
SDS, 20% glycerol, 0.01% Bromophenol blue). Subsequently, the
eluted proteins were separated by 5% SDS-PAGE, and analysed
by Western blotting using specific antibodies recognizing FLAG
(Sigma) and HA (Roche) respectively.
Luciferase assays
The reporter gene constructs and expression vectors indicated
in the figures were transfected into Hep3B cells which were seeded
onto a 24-well plate. After 48 hrs, the luciferase activities were
quantified with a luminometer (Mithras LB940; Berthold, Bad
Wildbad, Germany) using Dual-Glo Luciferase Assay System
(Promega) in accordance with the manufacturer’s instructions.
The data represented relative firefly luciferase activity normalized
with the Renilla luciferase activity of the pcDNA3.1(+) Rluc.
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Total RNA was isolated using Trizol (Invitrogen) and treated
with RNase free DNase I (Roche), subsequently the isolated RNA
was subjected to a random primed reverse transcriptase reaction
using ReverTraAce (Toyobo, Osaka, Japan). The expression levels
of SRCAP and p400 mRNAs were quantified using SYBR Premix
Ex TaqII (Takara, Otsu, Japan) by the Mx3000P quantitative
PCR System (Stratagene, La Jolla, CA). Each procedure was
performed according to manufacturer’s protocol. The quantifica-
tion data were normalized with the amount of glyceraldehyde-3-
phosphate dehydrogenase (G3PDH) mRNA, were expressed in
relative expression amount compared with that of non-specific
shRNA-transfected cells. The following specific primer sets were
used in this study: SRCAP sense primer: 59- CCCCCTGCT-
TCTCGCCTGGA -39; SRCAP antisense primer: 59- ACG-
CCTCTGGGCCTCTGCAT -39); p400 sense primer: 59-
AGGCGACAGGGAGAGTCGCA -39; p400 antisense primer:
59- GGATGGCTTCAGCCACCGCA -39; G3PDH sense primer:
59- CTACTGGCGCTGCCAAGGC -39; G3PDH antisense
primer: 59- GTGGGTGTCGCTGTTGAAGTC -39.
Nuclear extraction and immunoblotting
Nuclear extraction from HEK293 cells was performed using
CelLytic NuCLEAR Extraction Kit (Sigma) according to the
manufacturer’s protocol. Anti-Histone H1 antibody (AbCam,
Cambridge, UK) was used as a control of nuclear fraction, and
anti-actin antibody (Becton Dickinson, San Jose, CA) was used as a
loading control.
HEK293 cells were transfected with shRNA expression vector
which specifically targets to SRCAP or p400 mRNA. After 48 hrs,
the cells were harvested, and then lysed by lysis buffer (25 mM
Tris-HCl [pH 7.5], 150 mM NaCl, 1% NP-40) supplemented
with a protease inhibitor cocktail (Complete Mini; Roche). After
the cell debris was removed by centrifugation, and the superna-
tants were subjected to Western blotting analysis. Specific anti-
bodies against SRCAP (Santa Cruz Biotechnology, Santa Cruz,
CA) and p400 (Abnova, Taipei, Taiwan) used for detection of
endogenously expressed SRCAP and p400 proteins, respectively.
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